◎ Sugi Atlas

Atlas / Drug / Epinephrine

Epinephrine

drug
On this page

Also known as (-)-(r)-epinephrine(-)-epinephrineAdren coAdrenaclickAdrenalinAdrenalineAdrenalinumAna-guardAnapenAnaphylactic shock drug kitAsma-vydrinAsthmahalerAuvi-qAna-kitBronkaid mistBrovonEmeradeEpi e z pen jrEpinefrina

Summary

Epinephrine (CHEMBL679) is an approved small-molecule hormone (ATC R03AA01) targeting ADRA1A, ADRA1B, and ADRA1D; indicated across 56 conditions including cardiac arrest and obstructive lung disease.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: R03AA01 (+7 more)
  • Targets: 10 (ADRA1A, ADRA1B, ADRA1D…)
  • Indications: 56 conditions
  • Clinical trials: 271
  • Chemistry: 183.2 Da · C9H13NO3

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL679
NameEpinephrine
TypeSmall molecule
Max phase4
FDA approvedno
PubChem CID5816
ChEBICHEBI:28918
ATCR03AA01, S01EA51, R01AA14, B02BC09, S01EA01, A01AD01, C01CA24, R03AK01
Molecular formulaC9H13NO3
Molecular weight183.2
InChIKeyUCTWMZQNUQWSLP-VIFPVBQESA-N

SMILES: CNC[C@@H](C1=CC(=C(C=C1)O)O)O

IUPAC name: 4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol

ChEBI definition: The R-enantiomer of adrenaline. It is a hormone secreted by the adrenal glands resulting in the ‘fight-or-flight’ response.

Pharmacological roles (ChEBI): hormone, adrenergic agonist, vasodilator agent, α-adrenergic agonist, bronchodilator agent, vasoconstrictor agent, β-adrenergic agonist, sympathomimetic agent, mydriatic agent.

Other ChEBI roles (chemical / environmental): mouse metabolite.

Also known as: (-)-(r)-epinephrine, (-)-epinephrine, Adren co, Adrenaclick, Adrenalin, Adrenaline, Adrenalinum, Ana-guard, Anapen, Anaphylactic shock drug kit, Asma-vydrin, Asthmahaler

Parent form; salt/anhydrous children: CHEMBL227634, CHEMBL1200818, CHEMBL1256958, CHEMBL3183376

Patent coverage: 108,586 distinct patent families (318,480 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 318,052 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
ADRA1Aα1A-adrenoceptorFull agonist9.1P35348
ADRA1Bα1B-adrenoceptorFull agonist9.40%P35368
ADRA1Dα1D-adrenoceptorFull agonist7.70.2%P25100
CA1carbonic anhydrase 1Activation0%P00915
ADRA2Aα2A-adrenoceptorFull agonist5.50.1%P08913
ADRA2Bα2B-adrenoceptorFull agonist6.30.2%P18089
ADRA2Cα2C-adrenoceptorFull agonist6.70%P18825
ADRB1β1-adrenoceptorAgonist7.60%P08588
ADRB2β2-adrenoceptorFull agonist7.90.4%P07550
ADRB3β3-adrenoceptorFull agonist6.50.1%P13945

Broader ChEMBL bioactivity targets: 43 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Microtubule-associated protein tau, Lysine-specific demethylase 4E, Fructose-bisphosphate aldolase, ATP-dependent DNA helicase Q1, 4’-phosphopantetheinyl transferase ffp, Alpha-2A adrenergic receptor, Adrenergic receptor alpha-1, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor.

Bioactivity

ChEMBL activities: 77 potent at pChembl ≥ 5 of 102 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
ADRA1A8.59AC502.6nMCHEMBL_ACT_25229486
ADRA2A8.3Ki5nMCHEMBL_ACT_923521
ADRA2A8.25EC505.63nMCHEMBL_ACT_25751547
ADRA1A8.19AC506.5nMCHEMBL_ACT_25208334
ADRA1A8.17AC506.7nMCHEMBL_ACT_25229487
ADRA2A8.1IC508nMCHEMBL_ACT_259912
ADRA2A7.96AC5011nMCHEMBL_ACT_25220675
P193287.89Ki13nMCHEMBL_ACT_838955
Q8K4Z47.82EC5015nMCHEMBL_ACT_480183
P193287.82Ki15nMCHEMBL_ACT_846300
P158237.77IC5017nMCHEMBL_ACT_756572
ADRB27.66AC5022nMCHEMBL_ACT_25233371
ADRA2A7.52EC5030.2nMCHEMBL_ACT_16610370
ADRB37.51EC5031nMCHEMBL_ACT_2138184
DRD17.5AC5032nMCHEMBL_ACT_25180106
P193287.42Ki38nMCHEMBL_ACT_1022468
ADRB37.31EC5049nMCHEMBL_ACT_2138209
ADRA1B7.12EC5075nMCHEMBL_ACT_19313173
ADRA2A7.08AC5084nMCHEMBL_ACT_25220676
ADRA2A6.8Ki160nMCHEMBL_ACT_16610353
P193286.8Ki160nMCHEMBL_ACT_2335993
ADRB26.71Ki196nMCHEMBL_ACT_7649992
P158236.7Ki200nMCHEMBL_ACT_1134220
ADRA1D6.66Ki221nMCHEMBL_ACT_7649982
P106086.64EC50230nMCHEMBL_ACT_1022472
P106086.64EC50230nMCHEMBL_ACT_923526
P431406.59Ki254nMCHEMBL_ACT_7649978
ADRA2A6.56Ki276nMCHEMBL_ACT_7649984
ADRB26.55IC50284nMCHEMBL_ACT_7649991
ADRB16.54EC50290nMCHEMBL_ACT_19313172

Target pathways

Aggregated over 10 target gene(s): ADRA1A, ADRA1B, ADRA1D, CA1, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3.

Top Reactome pathways

40 total, by targets touching each:

PathwayTargetsGenes
Signal Transduction9ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
Signaling by GPCR9ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
Class A/1 (Rhodopsin-like receptors)9ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
Amine ligand-binding receptors9ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
GPCR downstream signalling9ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
Adrenoceptors9ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
GPCR ligand binding9ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
Hemostasis3ADRA2A, ADRA2B, ADRA2C
Metabolism3ADRA2A, ADRA2C, CA1
Adrenaline signalling through Alpha-2 adrenergic receptor3ADRA2A, ADRA2B, ADRA2C
Metabolism of proteins3ADRA2A, ADRA2C, ADRB2
G alpha (q) signalling events3ADRA1A, ADRA1B, ADRA1D
G alpha (12/13) signalling events3ADRA1A, ADRA1B, ADRA1D
G alpha (s) signalling events3ADRB1, ADRB2, ADRB3
G alpha (i) signalling events3ADRA2A, ADRA2B, ADRA2C
G alpha (z) signalling events3ADRA2A, ADRA2B, ADRA2C
Platelet activation, signaling and aggregation3ADRA2A, ADRA2B, ADRA2C
Platelet Aggregation (Plug Formation)3ADRA2A, ADRA2B, ADRA2C
Integration of energy metabolism2ADRA2A, ADRA2C
Adrenaline,noradrenaline inhibits insulin secretion2ADRA2A, ADRA2C
Regulation of insulin secretion2ADRA2A, ADRA2C
Surfactant metabolism2ADRA2A, ADRA2C
Erythrocytes take up carbon dioxide and release oxygen1CA1
Erythrocytes take up oxygen and release carbon dioxide1CA1
Cytokine Signaling in Immune system1CA1
Reversible hydration of carbon dioxide1CA1
O2/CO2 exchange in erythrocytes1CA1
Immune System1CA1
Membrane Trafficking1ADRB2
Transport of small molecules1CA1

Dominant GO biological processes

GO termTargets
signal transduction9
G protein-coupled receptor signaling pathway9
positive regulation of MAPK cascade9
adrenergic receptor signaling pathway8
adenylate cyclase-activating adrenergic receptor signaling pathway7
cell-cell signaling5
regulation of vasoconstriction5
adenylate cyclase-inhibiting adrenergic receptor signaling pathway5
adenylate cyclase-modulating G protein-coupled receptor signaling pathway4
adenylate cyclase-activating G protein-coupled receptor signaling pathway4
regulation of smooth muscle contraction4
phospholipase C-activating G protein-coupled receptor signaling pathway3
positive regulation of cytosolic calcium ion concentration3
neuron-glial cell signaling3
epidermal growth factor receptor signaling pathway3

Indications & clinical

Indications

56 indications (18 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
cardiac arrest4MONDO:0000745EFO:0004278
obstructive lung disease4MONDO:0002267HP:0006536
cardiovascular disorder4MONDO:0004995EFO:0000319
seasonal allergic rhinitis4MONDO:0005324EFO:0003956
urticaria4MONDO:0005492EFO:0005531
angioedema4MONDO:0010481EFO:0005532
sinusitis4MONDO:0005961EFO:0007486
toxic shock syndrome4MONDO:0001881EFO:0006834
allergic rhinitis4MONDO:0011786EFO:0005854
type III hypersensitivity disease4MONDO:0007004EFO:1001222
asthma4MONDO:0004979MONDO:0004979
allergic disease4MONDO:0005271MONDO:0005271
glaucoma4MONDO:0005041MONDO:0005041
bronchiolitis3MONDO:0002465HP:0011950
heart failure3MONDO:0005252EFO:0003144
pulpitis3MONDO:0006937EFO:1001139
perennial allergic rhinitis3MONDO:0024332EFO:1001417
non-small cell lung carcinoma3MONDO:0005233EFO:0003060
osteoarthritis, knee3MONDO:0005416EFO:0004616
gastric neoplasm3MONDO:0021085MONDO:0001056
benign muscle neoplasm3MONDO:0003061MONDO:0003061
male reproductive organ cancer3MONDO:0005836EFO:0007355
stroke disorder3MONDO:0005098EFO:0000712
bone fracture3MONDO:0005315EFO:0003931
lung neoplasm3MONDO:0021117MONDO:0008903
injury2MONDO:0021178EFO:0000546
hypospadias2MONDO:0005345EFO:0004209
ventricular fibrillation2MONDO:0000190EFO:0004287
acute lung injury2MONDO:0015796EFO:0004610
ventricular tachycardia2MONDO:0005477EFO:0005306
rotator cuff syndrome2MONDO:0007028EFO:1001250
breast neoplasm2MONDO:0021100MONDO:0007254
appendicitis2MONDO:0005649EFO:0007149
hypotensive disorder2MONDO:0005468EFO:0005251
musculoskeletal system disorder2MONDO:0002081EFO:0009676
hairy cell leukemia2MONDO:0018935EFO:1000956
anaphylaxis1MONDO:0100053MONDO:0100053
diabetes mellitus0MONDO:0005015EFO:0000400
skin neoplasm0MONDO:0002531EFO:0004198
parathyroid gland adenoma0MONDO:0006890EFO:1001087
depressive disorder0MONDO:0002050MONDO:0002050

15 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 271.

Phase distribution

PhaseTrials
Not specified96
PHASE489
PHASE327
PHASE223
PHASE114
PHASE2/PHASE39
EARLY_PHASE17
PHASE1/PHASE26

Top trials by phase / activity

NCTPhaseStatusTitle
NCT02118467PHASE4RECRUITINGVasoactive Drugs in Intensive Care Unit
NCT03826524PHASE4RECRUITINGEpinephrine Dose: Optimal Versus Standard Evaluation Trial
NCT05488847PHASE4ACTIVE_NOT_RECRUITINGOpioid-Free Pain Protocol After Shoulder Arthroplasty
NCT06418308PHASE4RECRUITINGIntrathecal Dexmedetomidine vs Epinephrine
NCT06694714PHASE4RECRUITINGSplit Face Study of the Duration of Local Anesthetics - Fourth Arm
NCT06834165PHASE4RECRUITINGStudy Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy
NCT07006168PHASE4RECRUITINGEffects Of Intra-Operative Intra-Articular Cocktail Injection In Patella Open Reduction And Internal Fixation
NCT07231614PHASE4NOT_YET_RECRUITINGAnesthetic Effectiveness of Lidocaine Versus Articaine in Dentistry
NCT07342413PHASE4NOT_YET_RECRUITINGStudy Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias
NCT00127907PHASE4COMPLETEDVasopressin and Epinephrine Versus Epinephrine Alone in Cardiac Arrest
NCT00270777PHASE4COMPLETEDImproving Safety of Antivenom in People Bitten by Snakes
NCT00289419PHASE4COMPLETEDIntraarticular Analgesia After Total Hip Arthroplasty, a Randomised Study
NCT00318292PHASE4COMPLETEDPreemptive Local Anesthesia in Vaginal Surgery
NCT00421967PHASE4TERMINATEDPostoperative Analgesia After Total Knee Arthroplasty
NCT00562627PHASE4COMPLETEDEfficacy of Multimodal Peri- and Intraarticular Drug Injections in Total Knee Arthroplasty
NCT00603083PHASE4COMPLETEDPostoperative Pain Treatment in Total Hip Arthroplasty: A Study to Assess the Effect of Local Analgesia
NCT00685672PHASE4COMPLETEDSafety of Epidural Fentanyl and Adrenalin During Childbirth
NCT00817466PHASE4UNKNOWNBronchiolitis All-study, SE-Norway
NCT00901628PHASE4COMPLETEDPeriarticular Multimodal Drug Injections in Total Knee Arthroplasty
NCT01217138PHASE4COMPLETEDMake up for the Epinephrine Autoinjector
NCT01239498PHASE4UNKNOWNSaline Injection - Assisted Anesthesia in Eyelid Surgery
NCT01243112PHASE4COMPLETEDEffectiveness Study of Different Local Anesthetic Mixtures
NCT01276821PHASE4COMPLETEDEfficacy of Nebulised Hypertonic Saline (3%) Among Children With Bronchiolitis.
NCT01304212PHASE4COMPLETEDEffectiveness of Analgesia in Total Knee Arthroplasty
NCT01367743PHASE4COMPLETEDStudy Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock
NCT01418118PHASE4COMPLETEDAssessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery
NCT01602692PHASE4COMPLETEDA Comparison of Tumescence in Breast Reduction Surgery
NCT01616069PHASE4COMPLETEDAssessment of Hemodynamic Response in Cardiopulmonary Bypass Graft After Cardiopulmonary Bypass Using Transesophegeal Echocardiography
NCT01706952PHASE4COMPLETEDComparison of Topical Vasoconstriction in Endoscopic Sinus Surgery
NCT01834820PHASE4COMPLETEDEpinephrine, Dexamethasone, and Hypertonic Saline in Bronchiolitis, Randomised Clinical Trial of Efficacy and Safety
NCT01862614PHASE4COMPLETEDTesting the Anesthetic Effectiveness of Buffered Articaine Injected Next to a Lower First Molar.
NCT01871857PHASE4COMPLETED7% Hypertonic Saline for Acute Bronchiolitis
NCT01887405PHASE4COMPLETEDComparative Evaluation of Handling Characteristics of Two Adrenaline Autoinjectors,EpiPen in Comparison With Jext
NCT01964586PHASE4COMPLETEDComparison of Preincisional Infiltrated Dexmedetomidine and Lidocaine Plus Adrenaline for Nasal Sephoplasty Surgery.
NCT01964781PHASE4COMPLETEDThe Effect of Topical Administration of Common Drugs on Postoperative Bleeding and Pain
NCT01989312PHASE4COMPLETEDThe Simultaneous Use of Supraclavicular and Distal Blocks
NCT02067078PHASE4COMPLETEDProtracted Effect of Combined Nerve Blocks After Total Knee Arthroplasty
NCT02238288PHASE4UNKNOWNRandomized Clinical Trial With Aminocaproic Acid in the Prevention of Exodontic Bleeding in Anticoagulants Patients
NCT02242201PHASE4COMPLETEDTotal Hip Arthroplasty (THA) Lumbar Plexus Verses Periarticular
NCT02270437PHASE4COMPLETEDSafety and Efficacy of Cocktail Periarticular Injection in Simultaneous Total Knee Arthroplasty

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

924 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
DIHYDROERGOTAMINEChEMBL + PubChemPhase 4 (approved)ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
TEGASERODChEMBL + PubChemPhase 4 (approved)ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
ARIPIPRAZOLEChEMBLPhase 4 (approved)ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
LABETALOLChEMBLPhase 4 (approved)ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
NOREPINEPHRINEChEMBLPhase 4 (approved)ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
CLOZAPINEChEMBL + PubChemPhase 4 (approved)ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB2, ADRB3
OLANZAPINEChEMBL + PubChemPhase 4 (approved)ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB2, ADRB3
PRAMIPEXOLEChEMBL + PubChemPhase 4 (approved)ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
TAMSULOSINChEMBL + PubChemPhase 4 (approved)ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2
BREXPIPRAZOLEChEMBLPhase 4 (approved)ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2
BROMOCRIPTINEChEMBLPhase 4 (approved)ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
CARVEDILOLChEMBLPhase 4 (approved)ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
DOBUTAMINEChEMBLPhase 4 (approved)ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, CA1
DOXAZOSINChEMBLPhase 4 (approved)ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB2, ADRB3
EBASTINEChEMBLPhase 4 (approved)ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB3
HALOPERIDOLChEMBLPhase 4 (approved)ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB2, ADRB3
PHENYLEPHRINEChEMBLPhase 4 (approved)ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
THIORIDAZINEChEMBLPhase 4 (approved)ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
SPIRAMIDEChEMBLPhase 2ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2
CRIZOTINIBChEMBL + PubChemPhase 4 (approved)ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
DESLORATADINEChEMBL + PubChemPhase 4 (approved)ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
PROPOXYPHENEChEMBL + PubChemPhase 4 (approved)ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
PYRAZINAMIDEChEMBL + PubChemPhase 4 (approved)ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
AMITRIPTYLINEChEMBLPhase 4 (approved)ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2
AMLODIPINEChEMBLPhase 4 (approved)ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2C, ADRB2, ADRB3
ASTEMIZOLEChEMBLPhase 4 (approved)ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB3
AZELASTINEChEMBLPhase 4 (approved)ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1
CARIPRAZINEChEMBLPhase 4 (approved)ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1
CLEMASTINEChEMBLPhase 4 (approved)ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2
CLOMIPRAMINEChEMBLPhase 4 (approved)ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2
CLOTRIMAZOLEChEMBLPhase 4 (approved)ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
DIETHYLSTILBESTROLChEMBLPhase 4 (approved)ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB3
DOMPERIDONEChEMBLPhase 4 (approved)ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2
ERGOTAMINEChEMBLPhase 4 (approved)ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2
NAFTOPIDILChEMBLPhase 4 (approved)ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1
NEFAZODONEChEMBLPhase 4 (approved)ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB3
NORTRIPTYLINEChEMBLPhase 4 (approved)ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2
PIMOZIDEChEMBLPhase 4 (approved)ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
PROCHLORPERAZINEChEMBLPhase 4 (approved)ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB3
RISPERIDONEChEMBLPhase 4 (approved)ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB2
SERTINDOLEChEMBLPhase 4 (approved)ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1
SILODOSINChEMBLPhase 4 (approved)ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB2
VILAZODONEChEMBLPhase 4 (approved)ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB2
LISURIDEChEMBLPhase 3ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2
YOHIMBINEChEMBLPhase 3ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB2
PIZOTYLINEChEMBLPhase 2ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB2
AlogliptinPubChemApprovedADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
BosentanPubChemApprovedADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
FidaxomicinPubChemApprovedADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
Tiotropium Bromide MonohydratePubChemApprovedADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
ACLIDINIUM BROMIDEChEMBL + PubChemPhase 4 (approved)ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2
AfatinibChEMBL + PubChemPhase 4 (approved)ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2
CHENODIOLChEMBL + PubChemPhase 4 (approved)ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2
CLOFARABINEChEMBL + PubChemPhase 4 (approved)ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2
OLODATEROLChEMBL + PubChemPhase 4 (approved)ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2
RIFAMPINChEMBL + PubChemPhase 4 (approved)ADRA1A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
ALFUZOSINChEMBLPhase 4 (approved)ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
AMOXAPINEChEMBLPhase 4 (approved)ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB2
APRACLONIDINEChEMBLPhase 4 (approved)ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
ASENAPINEChEMBLPhase 4 (approved)ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot